Literature DB >> 1689087

Reciprocal/dichotomic expression of vimentin and B cell differentiation antigens in Reed-Sternberg's cells.

J Tamaru1, A Mikata, K Azuma, T Takagi.   

Abstract

An immunohistochemical study of 63 cases of Hodgkin's disease was undertaken using formalin-fixed paraffin embedded tissue sections. The antibodies used were against L26, LN-1, LN-2, EMA (epithelial membrane antigen), Leu-M1, Vimentin, UCHL-1, S-100, and lysozyme. Hodgkin's disease could be divided into three groups: the first group was LN-1+/L26+/vimentin-, the second LN-1-/L26+/vimentin+, and the third LN-1-/L26-/vimentin+). Sixteen cases of follicular lymphomas were also examined and were all positive for LN-1 and L26 and negative for vimentin. Thus the vimentin negativity of the first group, including 7 nodular lymphocyte-predominant cases, gives further evidence of their germinal center B-cell origin. Since vimentin is expressed mainly in the immature stage of B-lymphocytes, the second group of Hodgkin's disease may represent immature B-cell Hodgkin's disease. In the third group, vimentin was present in Reed-Sternberg's (RS) and Hodgkin's (H) cells in 45 of the 48 cases (92.5%). In none of 48 cases were these cells positive for S-100 or lysozyme, but strong vimentin-positivity still suggested monocytic or histiocytic origin. The results of our study suggest, at least, divergent origin of RS's and H's cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689087     DOI: 10.1007/bf01678980

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  57 in total

1.  Biochemical and ultrastructural study of Leu M1 antigen in Reed-Sternberg cells: comparison with granulocytes and interdigitating reticulum cells.

Authors:  S M Hsu; L C Huang; P L Hsu; Z H Ge; Y S Ho; F Cuttita; J Mulshine
Journal:  J Natl Cancer Inst       Date:  1986-08       Impact factor: 13.506

2.  Anti-Leu-3a antibody reactivity with Reed-Sternberg cells of Hodgkin's disease.

Authors:  K Oka; N Mori; M Kojima
Journal:  Arch Pathol Lab Med       Date:  1988-02       Impact factor: 5.534

3.  Visualization of a system of filaments 7-10 nm thick in cultured cells of an epithelioid line (Pt K2) by immunofluorescence microscopy.

Authors:  M Osborn; W W Franke; K Weber
Journal:  Proc Natl Acad Sci U S A       Date:  1977-06       Impact factor: 11.205

4.  Complement receptor B lymphocytes in nodular sclerosing Hodgkin's disease.

Authors:  J Cossman; M J Deegan; B Schnitzer
Journal:  Cancer       Date:  1977-05       Impact factor: 6.860

5.  Immunoelectron microscopic study of Hodgkin's disease.

Authors:  N Mori; K Oka; H Sakuma; R Tsunoda; M Kojima
Journal:  Cancer       Date:  1985-12-01       Impact factor: 6.860

6.  Occurrence and patterns of muramidase containing cells in Hodgkin's disease, non-Hodgkin's lymphomas, and reactive hyperplasia.

Authors:  H J Ree; J Y Song; L A Leone; J P Crowley; H Fanger
Journal:  Hum Pathol       Date:  1981-01       Impact factor: 3.466

7.  Monoclonal antibody to keratin filaments, specific for glandular epithelia and their tumors. Use in surgical pathology.

Authors:  F Ramaekers; A Huysmans; O Moesker; A Kant; P Jap; C Herman; P Vooijs
Journal:  Lab Invest       Date:  1983-09       Impact factor: 5.662

8.  Nodular paragranuloma and progressively transformed germinal centers. Ultrastructural and immunohistologic findings.

Authors:  S Poppema; E Kaiserling; K Lennert
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1979

9.  In situ immunologic characterization of cellular constituents in lymph nodes and spleens involved by Hodgkin's disease.

Authors:  S Poppema; A K Bhan; E L Reinherz; M R Posner; S F Schlossman
Journal:  Blood       Date:  1982-02       Impact factor: 22.113

10.  Alteration of vimentin intermediate filament expression during differentiation of human hemopoietic cells.

Authors:  K Dellagi; W Vainchenker; G Vinci; D Paulin; J C Brouet
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

View more
  2 in total

1.  Classical Hodgkin's disease. Clinical impact of the immunophenotype.

Authors:  R von Wasielewski; M Mengel; R Fischer; M L Hansmann; K Hübner; J Franklin; H Tesch; U Paulus; M Werner; V Diehl; A Georgii
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

2.  Co-expression of Epstein-Barr virus latent membrane protein and vimentin in "aggressive" histological subtypes of Hodgkin's disease.

Authors:  A Carbone; A Gloghini; I Zanette; B Canal; A Rizzo; R Volpe
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.